What the six lenses say about NOVARTIND — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.
How NOVARTIND’s own sector index is moving — context for reading the stock’s six lenses.
Six-lens read
The actual numbers
Full 8-quarter history in the financials table below.
The actual numbers
Every filing in the corporate-announcements panel below.
The actual numbers
Decile — each lens’s 0–100 score is ranked against every Micro-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.
Conviction — the average of the two active conviction-lens deciles (Technical & Flow):
Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.
Glass box
Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.
Policy
Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.
PLI Scheme — Pharmaceuticals & API
Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices
Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-07.
| Baseline | 1D | 1W | 1M | 3M | 6M | 12M |
|---|---|---|---|---|---|---|
Nifty 50 Large-cap anchor | +1.9pp | +11.9pp | +5.3pp | +16.1pp | +129.4pp | +129.4pp |
Nifty 500 Broad-market baseline | +2.0pp | +12.0pp | +4.3pp | +14.9pp | +115.7pp | +115.7pp |
Sector Own-sector index | — | — | +4.0pp | +11.9pp | +143.5pp | +141.2pp |
From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).
Trend
NOVARTIND daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.
Relative strength
NOVARTIND ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.
TradingView composite technical analysis — multi-timeframe consensus
Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.
No quarterly financials available.
Filings to the exchange — capital actions, earnings and governance. Most recent first.
No recent corporate announcements.
Ownership
Mutual funds holding NOVARTIND (2)
| Fund | Weight | AUM ₹cr | Grade |
|---|---|---|---|
| HDFC Pharma and Healthcare Reg Gr | 0.51% | 2,940 | |
| Bandhan Healthcare Reg Gr | 1.54% | 319 |
ETFs holding NOVARTIND (0)
No tracked ETF holds NOVARTIND ≥0.5%.